Johnson & Johnson (JNJ) | Stock Overview & Key Data
Johnson & Johnson Performance Comparison
Stock Range
Today's Range
Low: $176.72
High: $178.80
on September 12, 2025
52 Week Range
Low: $140.68
High: $181.16
on January 10, 2025
on August 22, 2025
All-Time High: $186.69 on April 25, 2022
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$428.8B
EPS
9.35
P/E Ratio (TTM)
19.04
Forward P/E
16.80
P/B Ratio
5.46
PEG Ratio
1.06
Div. Yield
2.47%
ROE
30.21%
Beta
0.391
Debt to Equity
64.69
Financial Highlights
Profitability
Gross Margin
67.87%
Operating Margin
28.91%
Profit Margin
25.00%
Returns and Earnings
Return on Assets (TTM)
7.61%
Return on Equity (TTM)
30.21%
EBITDA
$31.8B
Net Income (TTM)
$22.7B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$37.65
Quarterly Revenue Growth (YoY)
5.80%
Quarterly Earnings Growth (YoY)
18.20%
Dividend Information
Last 12-Month Dividend
$3.72
Current Dividend Yield
2.47%
3-Year Average Dividend Yield
0.75%
3-Year Average Annual Dividend
$3.97
3-Year Total Dividends
$11.92
Ex-Dividend Date
February 18, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson JNJ | 428.83B Mega-cap | -0.21% | 3.06% | 13.66% | 9.34% | 23.64% | 7.58% | 6.24% | 19.36% |
| Eli Lilly and LLY | 691.79B Mega-cap | 3.88% | 18.13% | -6.98% | -8.09% | -2.91% | -18.22% | 144.55% | 389.97% |
| AbbVie ABBV | 385.71B Mega-cap | 2.72% | 9.92% | 13.47% | 2.96% | 21.68% | 12.41% | 51.55% | 142.28% |
| Merck & Co MRK | 206.84B Mega-cap | -2.24% | 3.13% | 1.21% | -11.29% | -16.50% | -28.53% | -5.60% | 1.14% |
| Amgen AMGN | 148.80B Large-cap | -2.56% | -3.01% | -7.03% | -11.56% | 6.60% | -16.83% | 19.62% | 11.61% |
| Gilead Sciences GILD | 142.13B Large-cap | -0.43% | -4.56% | 2.23% | 0.49% | 24.67% | 38.33% | 74.62% | 76.10% |
Ownership & Short Interest
Insider Ownership
0.06%
Institutional Ownership
74.37%
Shares Short
19M
Short Ratio
2.26
Short % of Shares Outstanding
0.78%
Average 10-Day Volume
7M
Average 90-Day Volume
8M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is JNJ's 52-week high and low?
- In the last 52 weeks, Johnson & Johnson reached a high of $181.16 (on August 22, 2025) and a low of $140.68 (on January 10, 2025).
- What is the market cap and P/E ratio for JNJ?
- Curious about Johnson & Johnson's size and valuation? Its market capitalization stands at 428.83B. When it comes to valuation, the P/E ratio (trailing twelve months) is 19.04, and the forward P/E (looking ahead) is 16.80.
- Does JNJ pay dividends? If so, what's the yield?
- Yes, Johnson & Johnson is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 2.47%, and the company has paid an average of $3.97 per share annually over the past 3 years.
- Who are Johnson & Johnson's main competitors or similar companies to consider before investing?
When looking at Johnson & Johnson, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY691.79B Healthcare Drug Manufacturers - General -18.22% 144.55% AbbVie
ABBV385.71B Healthcare Drug Manufacturers - General 12.41% 51.55% Merck & Co
MRK206.84B Healthcare Drug Manufacturers - General -28.53% -5.60% Amgen
AMGN148.80B Healthcare Drug Manufacturers - General -16.83% 19.62% Gilead Sciences
GILD142.13B Healthcare Drug Manufacturers - General 38.33% 74.62% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Johnson & Johnson? (e.g., ROE, Debt/Equity)
- To get a sense of Johnson & Johnson's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 30.21%, the Debt to Equity ratio from the most recent quarter is 64.69, and its Gross Profit Margin stands at 67.87%.
- What is the recent revenue and earnings growth for JNJ?
- Looking at Johnson & Johnson's growth, its revenue over the trailing twelve months (TTM) was $91B. Compared to the same quarter last year (YoY), quarterly revenue grew by 5.80%, and quarterly earnings saw a YoY growth of 18.20%.
- How much of JNJ stock is held by insiders and institutions?
- Wondering who owns Johnson & Johnson stock? Company insiders (like executives and directors) hold about 0.06% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 74.37%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.